%0 Journal Article
%A Pohl, Lara C
%A Leitheiser, Maximilian
%A Obrecht, Denise
%A Schweizer, Leonille
%A Wefers, Annika K
%A Eckhardt, Alicia
%A Raffeld, Mark
%A Sturm, Dominik
%A Pajtler, Kristian W
%A Rutkowski, Stefan
%A Fukuoka, Kohei
%A Ichimura, Koichi
%A Bockmayr, Michael
%A Schüller, Ulrich
%T Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
%J Acta neuropathologica
%V 147
%N 1
%@ 0001-6322
%C Heidelberg
%I Springer
%M DKFZ-2024-00207
%P 24
%D 2024
%X The diagnosis of ependymoma has moved from a purely histopathological review with limited prognostic value to an integrated diagnosis, relying heavily on molecular information. However, as the integrated approach is still novel and some molecular ependymoma subtypes are quite rare, few studies have correlated integrated pathology and clinical outcome, often focusing on small series of single molecular types. We collected data from 2023 ependymomas as classified by DNA methylation profiling, consisting of 1736 previously published and 287 unpublished methylation profiles. Methylation data and clinical information were correlated, and an integrated model was developed to predict progression-free survival. Patients with EPN-PFA, EPN-ZFTA, and EPN-MYCN tumors showed the worst outcome with 10-year overall survival rates of 56
%K Humans
%K Ependymoma
%K Progression-Free Survival
%K Protein Processing, Post-Translational
%K DNA methylation (Other)
%K Ependymoma (Other)
%K Machine learning (Other)
%K Molecular types (Other)
%K Survival (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38265522
%R 10.1007/s00401-023-02674-x
%U https://inrepo02.dkfz.de/record/287282